Terry Riss's Biography

Terry Riss, Senior Product Manager, Cell Health, Promega Corporation

Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and held several R&D and Project Management positions since. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Manager, Cell Health involved in outreach educational training activities including validating assay systems applied to 3D cell culture models. Dr. Riss also serves as an editor of the In Vitro Cell-Based Assays section of the Assay Guidance Manual hosted by The National Center for Advancing Translational Sciences (NCATS) at the NIH.

Factors To Consider When Choosing Organoids As a Fit-For-Purpose Model

Friday, 15 November 2019 at 08:30

Add to Calendar ▼2019-11-15 08:30:002019-11-15 09:30:00Europe/LondonFactors To Consider When Choosing Organoids As a Fit-For-Purpose ModelMicrofluidics and Organ-on-a-Chip Asia 2019 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com

There is a broad spectrum of 3D cell culture models available to perform biological research ranging from individual tumor spheroids to complex microfluidic representations of a human-on-a-chip. Choosing an appropriate model must include a consideration of exactly what you want to know at the end of the experiment, the capabilities of the model, the investment you are willing to make and the limitations of available assay technologies. We will provide an overview of factors to consider when choosing an appropriate model system that is driving to an increased use of organoids.

Add to Calendar ▼2019-11-14 00:00:002019-11-15 00:00:00Europe/LondonMicrofluidics and Organ-on-a-Chip Asia 2019Microfluidics and Organ-on-a-Chip Asia 2019 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors